Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndromeMaria Antonietta Aloe Spiriti, Maria Concetta Petti, Marta Francesconi et al.|Annals of Hematology|2004Cited by 110
Phase III trial comparing 3–6 months of adjuvant FOLFOX4/XELOX in stage II–III colon cancer: safety and compliance in the TOSCA trialSara Lonardi, Alberto Sobrero, Gerardo Rosati et al.|Annals of Oncology|2016Cited by 56
Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II studyStefano Cascinu, Michela Cinquini, Rossana Berardi et al.|Digestive and Liver Disease|2013Cited by 52
The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenibLuca Faloppi, Stefano Cascinu, Maristella Bianconi et al.|Oncotarget|2015Cited by 46
Observational study on quality of life, safety, and effectiveness of first‐line cetuximab plus chemotherapy in <i><scp>KRAS</scp></i> wild‐type metastatic colorectal cancer patients: the ObservEr StudyCarmine Pinto, Francesco Di Costanzo, Francesca Di Fabio et al.|Cancer Medicine|2016Cited by 26